Institutional Shareholder Services has recommended Pfizer investors reject a proposal on executive compensation at its ...

Institutional Shareholder Services has recommended Pfizer investors reject a proposal on executive compensation due to ...

A pair of top Democratic lawmakers asked the U.S. securities regulator on Wednesday to preserve records related to President ...

Major pharmaceutical companies reap most of their profits in the U.S. but shift their tax burdens to low-tax havens such as ...

Rep. Ami Bera (D-Calif.) wants the House to regroup its task force on artificial intelligence, arguing the government should ...

In the closing of the recent trading day, Pfizer (PFE) stood at $24.70, denoting a +0.65% change from the preceding trading day.

The latest decision makes Pfizer's Abrysvo the first RSV vaccine approved for use in non-pregnant adults under 50 years of ...

One of the most promising aspects of AI and its integration into the pharmaceutical industry is the technology’s potential to ...

Pfizer in 2019 sold $20 billion of drugs in the U.S. Its federal tax bill? Zero. That revelation was part of a Senate Finance ...

Wockhardt will deepen its novel antibiotics pipeline over the next five years and focus on building a biosimilar business for ...

In a report released today, Geoff Meacham from Citi maintained a Hold rating on Pfizer (PFE – Research Report), with a price target of $27.00.

With the recently announced layoffs of 3,500 FDA staffers and exits of branch directors Patrizia Cavazzoni and Peter Marks, ...